Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26546116 | 0.79 | ABCG2 (0.48) | ARABCG2EGFRERBB2BACE2 | |
| SCHEMBL290322 | 0.78 | TSHR (0.48) | TSHRMAOAMAOBDRD4 | |
| SCHEMBL29825887 | 0.78 | TSHR (0.48) | TSHRMAOAMAOBDRD4 | |
| SCHEMBL26125756 | 0.78 | KDM4E (0.54) | EGFRERBB2TSHRMAOAMAOB | |
| SCHEMBL27561674 | 0.76 | AR (0.36) | LRRK2ARABCG2EGFRERBB2 | |
| SCHEMBL26128386 | 0.75 | AKR1C3 (0.52) | TSHR | |
| SCHEMBL30294516 | 0.74 | ALDH1A1 (0.44) | LRRK2MAOAMAOB | |
| SCHEMBL22852826 | 0.74 | ALDH1A1 (0.44) | LRRK2MAOAMAOB | |
| SCHEMBL2692061 | 0.73 | MAOB (0.42) | EGFRERBB2TSHRMAOAMAOB | |
| SCHEMBL13384748 | 0.72 | BCL6 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| WO-2008037784-A1 | QUINOLINONE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | CHRM1, CYP2C8, CCR8 | LRRK2 1409/4885AR 427/4885ABCG2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.